Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic UC-MSCs for Ankylosing Spondylitis
NCT05962762Phase 1Not yet recruiting
- Start
- Aug 2023
- Primary completion
- Dec 2026
- Modality
- Stem Cell Therapies
01
Overview
Phase 1, open-label, single-arm trial of human umbilical cord mesenchymal stem cells in ankylosing spondylitis (AS). Primary endpoints: Adverse Event (AE) at 1 year and Maximum tolerated dose at 1 year. Planned start Aug 2023; status: not yet recruiting.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT05962762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05962762.